Clinical Trial

Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

Study acronym: VESPER-4
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks. The primary endpoint will be assessed after 64 weeks of treatment with the secondary at 84 weeks.
Protocol Amendment History 3 changes
notable Trial sites reduced: 195 -> 170 locations 2026-06-12
notable Sponsor changed: Metsera, a wholly owned subsidiary of Pfizer -> Pfizer 2026-05-30
notable Trial sites expanded: 5 -> 196 locations 2026-04-22
Trial Details
NCT Number NCT07311850
Lead Sponsor Pfizer
Conditions Obesity and Overweight
Enrollment 3,501 participants
Start Date 2025-12-19
Primary Completion 2027-09-21 (estimated)
Study Completion 2028-04-25 (estimated)
Updated on ClinicalTrials.gov 2026-07-06